Article citationsMore>>

Chen, Z., Cheng, K., Walton, Z., Wang, Y., Ebi, H., Shimamura, T., Liu, Y., Tupper, T., Ouyang, J., Li, J., et al. (2012) A Murine Lung Cancer Co-Clinical Trial Identifies Genetic Modifiers of Therapeutic Response. Nature, 483, 613-617. https://doi.org/10.1038/nature10937

has been cited by the following article:

• TITLE: Construction of Enriched Resource for Primary Therapeutic Targets of Approved and Clinical Trial Drugs

  AUTHORS: Hong Yang, Chunyan Yu, Yinghong Li, Feng Zhu

  KEYWORDS: Drug, Drug Target, Indication, Protein Target of a Drug, Target of Disease

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.5 No.3, March 10, 2017

  ABSTRACT: An assessment of the efficacy targets of drugs that represent an opportunity for targeted therapy is fundamental to the development of post-genomic research strategies within the pharmaceutical industry. Identification and validation of efficacy target is an important process in drug discovery and development. Extensive drug discovery efforts have yielded many approved and candidate drugs. Although sever drug databases provide the drug and their corresponding targets, there is an insufficient coverage of the clinical trial drugs over the past decades. Here, we conduct a comprehensive survey for current clinical trial drugs, therapeutic targets. The analysis contents include: 1) collect clinical trial drugs from different sources, 2) By analysis of the literature, we summarize the criteria for assign therapeutic targets for each drug based on its indication. The knowledge of these drugs and their targets is useful not only for drug discovery and development of targeted therapy, but also for facilitating the discovery of systems pharmacology.